Sclerotherapy with OK-432 for recurrent cystic thyroid nodule

Hang-Seok Chang, Jong Ho Yoon, Woung Youn Chung, Cheong Soo Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We have adopted OK-432 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of OK-432. From 1992 through 1993, 48 patients with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for malignancy, were used for this study. The OK-432 solution was prepared by dissolving 0.1 mg of OK-432 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per patient was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7%) patients experienced an almost complete disappearance (<0.5 cm in diameter) of the cystic lesion, and 12 (25%) patients responded partially by having it decrease by more than half (>0.5 cm in diameter) of the initial cyst size, and none of these patients required further treatment. The remaining 4 (8.3%) patients showed insufficient resolution despite 3 courses of therapy and 2 of these patients underwent thyroidectomy, in which the lesion proved benign in both cases. All of the patients tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2%) patients for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, OK-432 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.

Original languageEnglish
Pages (from-to)367-371
Number of pages5
JournalYonsei medical journal
Volume39
Issue number4
DOIs
Publication statusPublished - 1998 Jan 1

Fingerprint

Picibanil
Thyroid Nodule
Sclerotherapy
Therapeutics
Sclerosing Solutions
Thyroidectomy
Cysts
Fever

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chang, Hang-Seok ; Yoon, Jong Ho ; Chung, Woung Youn ; Park, Cheong Soo. / Sclerotherapy with OK-432 for recurrent cystic thyroid nodule. In: Yonsei medical journal. 1998 ; Vol. 39, No. 4. pp. 367-371.
@article{dbb747b51c7f43458e059b3e9e5be3e8,
title = "Sclerotherapy with OK-432 for recurrent cystic thyroid nodule",
abstract = "We have adopted OK-432 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of OK-432. From 1992 through 1993, 48 patients with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for malignancy, were used for this study. The OK-432 solution was prepared by dissolving 0.1 mg of OK-432 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per patient was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7{\%}) patients experienced an almost complete disappearance (<0.5 cm in diameter) of the cystic lesion, and 12 (25{\%}) patients responded partially by having it decrease by more than half (>0.5 cm in diameter) of the initial cyst size, and none of these patients required further treatment. The remaining 4 (8.3{\%}) patients showed insufficient resolution despite 3 courses of therapy and 2 of these patients underwent thyroidectomy, in which the lesion proved benign in both cases. All of the patients tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2{\%}) patients for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, OK-432 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.",
author = "Hang-Seok Chang and Yoon, {Jong Ho} and Chung, {Woung Youn} and Park, {Cheong Soo}",
year = "1998",
month = "1",
day = "1",
doi = "10.3349/ymj.1998.39.4.367",
language = "English",
volume = "39",
pages = "367--371",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Sclerotherapy with OK-432 for recurrent cystic thyroid nodule. / Chang, Hang-Seok; Yoon, Jong Ho; Chung, Woung Youn; Park, Cheong Soo.

In: Yonsei medical journal, Vol. 39, No. 4, 01.01.1998, p. 367-371.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sclerotherapy with OK-432 for recurrent cystic thyroid nodule

AU - Chang, Hang-Seok

AU - Yoon, Jong Ho

AU - Chung, Woung Youn

AU - Park, Cheong Soo

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We have adopted OK-432 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of OK-432. From 1992 through 1993, 48 patients with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for malignancy, were used for this study. The OK-432 solution was prepared by dissolving 0.1 mg of OK-432 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per patient was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7%) patients experienced an almost complete disappearance (<0.5 cm in diameter) of the cystic lesion, and 12 (25%) patients responded partially by having it decrease by more than half (>0.5 cm in diameter) of the initial cyst size, and none of these patients required further treatment. The remaining 4 (8.3%) patients showed insufficient resolution despite 3 courses of therapy and 2 of these patients underwent thyroidectomy, in which the lesion proved benign in both cases. All of the patients tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2%) patients for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, OK-432 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.

AB - We have adopted OK-432 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of OK-432. From 1992 through 1993, 48 patients with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for malignancy, were used for this study. The OK-432 solution was prepared by dissolving 0.1 mg of OK-432 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per patient was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7%) patients experienced an almost complete disappearance (<0.5 cm in diameter) of the cystic lesion, and 12 (25%) patients responded partially by having it decrease by more than half (>0.5 cm in diameter) of the initial cyst size, and none of these patients required further treatment. The remaining 4 (8.3%) patients showed insufficient resolution despite 3 courses of therapy and 2 of these patients underwent thyroidectomy, in which the lesion proved benign in both cases. All of the patients tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2%) patients for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, OK-432 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.

UR - http://www.scopus.com/inward/record.url?scp=7344227933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344227933&partnerID=8YFLogxK

U2 - 10.3349/ymj.1998.39.4.367

DO - 10.3349/ymj.1998.39.4.367

M3 - Article

VL - 39

SP - 367

EP - 371

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -